Board of Directors

  • Leadership User
    Mr David Williams

    B.Ec (Hons), M.Ec, FAICD

    Non-executive Chairman

    Mr Williams was appointed as a Non-executive Director on 28 February 2014 and Chairman on 13 March 2014. Mr Williams is an experienced Director and investment banker with a proven track record in business development and strategy, as well as in corporate initiatives specializing in mergers and acquisitions and capital raising. He possesses 30 years’ experience working with and advising ASXlisted companies in the food, medical device and pharmaceutical sectors. Mr Williams was previously the Managing Director of Challenger Corporate Finance, Head of Mergers & Acquisitions – Melbourne, Société Générale Hambros, Head of Mergers & Acquisitions at ANZ McCaughan, and Australian Head of Mergers & Acquisitions Arthur Andersen & Co. He has been Chairman of Tassal Group Ltd and Austin Group Ltd and held numerous other Directorships including with Amcal Ltd and Select Harvests Ltd. Mr Williams is currently Chairman of ASX-listed Medical Developments International Ltd (ASX: MVP), and is Managing Director of corporate advisory firm Kidder Williams Ltd. Mr Williams resigned as Non-executive Director of IDT (ASX: IDT) on 19 May 2015.

  • Leadership User
    Mr Max Johnston

    Non-executive Director

    Mr. Johnston was appointed a Director of PolyNovo on 13 May 2014. Mr. Johnston held the position of President and Chief Executive Officer of Johnson & Johnson Pacific, a division of the world’s largest medical, pharmaceutical and consumer healthcare company for 11 years. Prior to joining Johnson & Johnson, Mr. Johnston’s career also included senior roles with Diageo and Unilever in Europe. Mr. Johnston has also held several prominent industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of ASMI. Mr. Johnston has had extensive overseas experience during his career in leading businesses in both Western and Central-Eastern Europe and Africa as well as the Asia-Pacific region. Mr. Johnston is currently a Non-Executive Director of Medical Developments International Ltd (ASX: MVP) and Enero Group Limited (ASX: EGG), and Non-executive Chairman of Probiotec Ltd (ASX: PBP).

  • Leadership User
    Mr Philip Powell

    BComm (Hons), ACA, F.Fin, MAICD

    Non-executive Director

    Mr. Powell was appointed a Director of PolyNovo on 13 May 2014 and was Acting Managing Director from 15 July 2014 to 13 February 2015. Mr. Powell has many years’ experience in investment banking specialising in capital raisings, Initial Public Offerings (IPOs), mergers and acquisitions and other successful corporate finance assignments across a diverse range of sectors including utilities, IT, pharma, financial services, food and agriculture. He spent 10 years in senior financial roles at OAMPS Ltd, a former ASX-listed financial services group, and 10 years in audit with Arthur Andersen & Co in Melbourne, Sydney and Los Angeles. Mr. Powell is currently a Non-Executive Director of Medical Developments International Ltd (ASX: MVP).

  • Leadership User
    Dr David McQuillan

    PhD

    Non-executive Director

    Dr. McQuillan was appointed a Director of PolyNovo on 6 August 2012. He has extensive technical, medical, scientific and regulatory knowledge, as well as merger and acquisition expertise. Dr. McQuillan was with LifeCell Inc/Kinetic Concepts Inc.(KCI) for 12 years, holding a number of senior roles, including Vice President for Research and Development at LifeCell and Senior Vice President of Advanced Research and Technology at KCI. He was Chief Science Officer for TELA Bio, a VC-funded development-stage biotechnology company from 2013 to 2015.

  • Leadership User
    Mr Leon Hoare

    Non-executive Director

    Mr. Hoare was appointed a Director of PolyNovo on 27 January 2016. Mr Hoare is also Managing Director of Lohmann & Rauscher (Australia and New Zealand), a privately owned, multinational medical device company. Previously Mr. Hoare was Managing Director of Smith & Nephew (Australia/NZ) until the end of 2015, one of Smith & Nephew’s largest global subsidiaries outside the US. He served as President of Smith & Nephew’s Asia-Pacific Advanced Wound Management (AWM) business for five years and was a member of the Global Executive Management for the AWM Division. In his 24 years with Smith & Nephew, he also held roles in marketing, divisional and general management. Mr. Hoare’s career also includes a senior role at Bristol-Myers Squibb in surgical products, and Vice Chair of Australia’s peak medical device body, Medical Technology Association of Australia. Mr. Hoare is currently a Non-Executive Director of Medical Developments International Ltd (ASX: MVP).

  • Leadership User
    Mr Bruce Rathie

    Non-executive Director

    Mr. Rathie is an experienced Company Director and lawyer. He practised as a partner in a large legal firm and acted as Senior In-house Counsel to Bell Resources Limited from 1980 to 1985. He studied for his MBA in Geneva and embarked on his investment banking career in 1986. He was Head of the Industrial Franchise Group at Salomon Smith Barney in the late 1990s and led Salomon’s roles in the Federal Government’s privatisation of Qantas, Commonwealth Bank (CBA3) and Telstra (T1). He has over 15 years’ experience as a professional Non-Executive Company Director. He is currently Chairman of DataDot Technology Limited (ASX: DDT), Vice Chairman of Capricorn Society Limited and Chairman of Capricorn Mutual Limited. In the medical device space, he was previously Chairman of Anteo Diagnostics Limited and a Director of Compumedics Limited and USCOM Limited. He has been a Non-Executive Director of PolyNovo since February 2010.

  • Leadership User
    Dr Robyn Elliott

    BSc (Hons) Chemistry

    PhD Inorganic Chemistry

    Dr Elliott is currently Senior Director for Strategic Expansion Projects at CSL Behring, previously she was the Managing Director at IDT Australia and commenced her career at DBL Faulding. Dr Elliott has a proven track record in product development, clinical trials, regulatory affairs, audits, quality management and operational strategy. At CSL, her worldwide experience in new plant development and strategy, regulatory affairs and audit will be invaluable to PolyNovo as the company scales its operations globally.